Copyright
©The Author(s) 2022.
World J Clin Cases. Dec 6, 2022; 10(34): 12566-12577
Published online Dec 6, 2022. doi: 10.12998/wjcc.v10.i34.12566
Published online Dec 6, 2022. doi: 10.12998/wjcc.v10.i34.12566
Figure 1 Virologic response among patients.
A: Percentage among all patients; B: Percentage among patients without cirrhosis; C: Percentage among patients with cirrhosis; D: Percentage among patients with HCV genotype 1; E: Percentage among patients with HCV genotype 3; F: Percentage among patients with HCV genotype 4.
- Citation: Abdulla M, Al Ghareeb AM, Husain HAHY, Mohammed N, Al Qamish J. Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C. World J Clin Cases 2022; 10(34): 12566-12577
- URL: https://www.wjgnet.com/2307-8960/full/v10/i34/12566.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i34.12566